Genomma Lab Internacional SAB de CV

Genomma Lab maintains a leveraged capital structure with total liabilities of 12.72 billion MXN against total equity of 11.11 billion MXN, resulting in a debt-to-equity ratio of 0.69. The company holds 2.86 billion MXN in cash and equivalents, which is insufficient to cover its 7.63 billion MXN in long-term debt, creating a net cash deficit. Liquidity is supported by a current ratio of 1.77, indicating adequate short-term asset coverage for current liabilities. Operating cash flow stands at 2.05 billion MXN, while free cash flow is 630.14 million MXN after capital expenditures of 574.62 million MXN.

Profitability metrics show a return on equity of 14.47% and a return on assets of 6.74%. The company generated 1.61 billion MXN in net income on 17.54 billion MXN in revenue, yielding a net margin of approximately 9.16%. Gross profit was 11.02 billion MXN, indicating a gross margin of 62.84%, while operating income was 3.76 billion MXN. These returns suggest efficient utilization of equity, though the absence of cohort median data prevents a direct comparative assessment of profitability relative to industry peers.

Revenue concentration and geographic exposure details are not provided in the available data, preventing an analysis of segment-specific performance or regional risk distribution. The company’s business activity is broadly classified as pharmaceuticals, but specific product lines or customer concentrations are not disclosed in the current snapshot.

Growth trajectory analysis is limited by the absence of historical period data in the input. Without multi-year revenue or net income trends, it is not possible to assess the company’s historical growth rate or momentum. The current financial snapshot reflects a single normalized period, offering a static view of performance rather than a dynamic trend.

Risk assessment indicates medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, highlighting reliance on operating cash flows to service debt obligations. The company has 1 billion shares outstanding, with no difference between basic and diluted shares, suggesting minimal immediate dilution pressure from options or convertible securities.

Recent analyst observations show a mean price target of 28.10 MXN and a median target of 29.00 MXN, implying significant upside from the current market price of 15.09 MXN. The mean recommendation is 2.29, with five buy ratings and two hold ratings, indicating positive sentiment among analysts. No strong-buy ratings were recorded, and the high price target is 30.00 MXN.